Claes Malm

1.5k total citations
28 papers, 849 citations indexed

About

Claes Malm is a scholar working on Hematology, Genetics and Public Health, Environmental and Occupational Health. According to data from OpenAlex, Claes Malm has authored 28 papers receiving a total of 849 indexed citations (citations by other indexed papers that have themselves been cited), including 23 papers in Hematology, 12 papers in Genetics and 7 papers in Public Health, Environmental and Occupational Health. Recurrent topics in Claes Malm's work include Acute Myeloid Leukemia Research (10 papers), Chronic Lymphocytic Leukemia Research (7 papers) and Chronic Myeloid Leukemia Treatments (7 papers). Claes Malm is often cited by papers focused on Acute Myeloid Leukemia Research (10 papers), Chronic Lymphocytic Leukemia Research (7 papers) and Chronic Myeloid Leukemia Treatments (7 papers). Claes Malm collaborates with scholars based in Sweden, Denmark and Netherlands. Claes Malm's co-authors include Ingemar Turesson, Magnus Adriansson, Fredrik Celsing, Gunnar Juliusson, Stig Lenhoff, Magnus Björkholm, Gunnar Birgegård, Lars Nilsson, Berit Markevärn and Björn Andréasson and has published in prestigious journals such as Journal of Clinical Oncology, Blood and Stem Cells.

In The Last Decade

Claes Malm

28 papers receiving 831 citations

Peers

Claes Malm
A. E. Watmore United Kingdom
Mordechai Shtalrid Israel
Odile Maarek France
Julian Topaly Germany
Françoise Brizard France
A. Nagler Israel
Lihui Wang China
B Heinze Germany
CM Rubin United States
Paul Virgo United Kingdom
A. E. Watmore United Kingdom
Claes Malm
Citations per year, relative to Claes Malm Claes Malm (= 1×) peers A. E. Watmore

Countries citing papers authored by Claes Malm

Since Specialization
Citations

This map shows the geographic impact of Claes Malm's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Claes Malm with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Claes Malm more than expected).

Fields of papers citing papers by Claes Malm

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Claes Malm. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Claes Malm. The network helps show where Claes Malm may publish in the future.

Co-authorship network of co-authors of Claes Malm

This figure shows the co-authorship network connecting the top 25 collaborators of Claes Malm. A scholar is included among the top collaborators of Claes Malm based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Claes Malm. Claes Malm is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Hägglund, Hans, Akif Selim Yavuz, Arta Dreimane, et al.. (2020). Graft‐versus‐mastocytosis effect after donor lymphocyte infusion: Proof of principle. European Journal Of Haematology. 106(2). 290–293. 3 indexed citations
2.
3.
Machaczka, Maciej, Jan‐Erik Johansson, Mats Remberger, et al.. (2012). Allogeneic hematopoietic stem cell transplant with reduced-intensity conditioning for chronic lymphocytic leukemia in Sweden: does donor T-cell engraftment 3 months after transplant predict survival?. Leukemia & lymphoma. 53(9). 1699–1705. 9 indexed citations
4.
Björkholm, Magnus, Åsa Rangert Derolf, Malin Hultcrantz, et al.. (2011). Treatment-Related Risk Factors for Transformation to Acute Myeloid Leukemia and Myelodysplastic Syndromes in Myeloproliferative Neoplasms. Journal of Clinical Oncology. 29(17). 2410–2415. 174 indexed citations
5.
Lazarević, Vladimir, Mats Remberger, Hans Hägglund, et al.. (2011). Myeloablative allogeneic stem cell transplantation for lymphoblastic lymphoma in Sweden: A retrospective study. American Journal of Hematology. 86(8). 709–710. 7 indexed citations
6.
Lazarević, Vladimir, Hans Hägglund, Mats Remberger, et al.. (2010). Long-term survival following allogeneic or syngeneic stem cell transplant for follicular lymphoma in Sweden. Leukemia & lymphoma. 52(1). 69–71. 3 indexed citations
7.
Merup, Mats, Vladimir Lazarević, Hareth Nahi, et al.. (2006). Different outcome of allogeneic transplantation in myelofibrosis using conventional or reduced‐intensity conditioning regimens. British Journal of Haematology. 135(3). 367–373. 41 indexed citations
8.
Samuelsson, Jan, Hans Carl Hasselbalch, Øystein Bruserud, et al.. (2004). A Phase II Trial of Pegylated Interferon α-2b in Polycythemia Vera and Essential Thrombocythemia. Clinical Responses, Effects on PRV-1 Expression and Impact on Quality of Life.. Blood. 104(11). 1518–1518. 3 indexed citations
9.
Juliusson, Gunnar, et al.. (2003). Adjusted Conditioning for Allogeneic Transplantation in a Single Center Setting: Mixed Chimerism Heralds Relapse. Leukemia & lymphoma. 44(4). 669–679. 6 indexed citations
10.
Axdorph, Ulla, Leif Stenke, Gunnar Grimfors, et al.. (2002). Intensive chemotherapy in patients with chronic myelogenous leukaemia (CML) in accelerated or blastic phase – a report from the Swedish CML Group. British Journal of Haematology. 118(4). 1048–1054. 16 indexed citations
11.
Juliusson, Gunnar, Fredrik Celsing, Ingemar Turesson, et al.. (2000). Frequent good partial remissions from thalidomide including best response ever in patients with advanced refractory and relapsed myeloma. British Journal of Haematology. 109(1). 89–96. 203 indexed citations
12.
Billström, Rolf, Bertil Johansson, Thoas Fioretos, et al.. (1997). Poor survival in t(8;21)(q22;q22)‐associated acute myeloid leukaemia with leukocytosis. European Journal Of Haematology. 59(1). 47–52. 35 indexed citations
13.
Ljungman, Per, Mark Lawler, Birgitta Åsjö, et al.. (1994). Infection of donor lymphocytes with human T lymphotrophic virus type 1 (HTLV‐I) following allogeneic bone marrow transplantation for HTLV‐I positive adult T‐cell leukaemia. British Journal of Haematology. 88(2). 403–405. 39 indexed citations
14.
Simonsson, Bengt, Gunnar Öberg, A. Killander, et al.. (1993). Intensive treatment in order to minimize the ph‐positive clone in chronic myelogenic leukemia. Stem Cells. 11(S3). 73–76. 15 indexed citations
15.
Vrethem, Magnus, et al.. (1993). Clinical, neurophysiological and immunological evidence of polyneuropathy in patients with monoclonal gammopathies. Journal of the Neurological Sciences. 114(2). 193–199. 55 indexed citations
16.
Vrethem, Magnus, et al.. (1992). Ig-secreting cells pass the blood-brain barrier: studies on κ and λ light chain secreting cells in plasma cell dyscrasia. Journal of Neuroimmunology. 41(2). 189–194. 13 indexed citations
17.
Wåhlin, Anders, et al.. (1991). Mitoxantrone and cytarabine versus daunorubicin and cytarabine in previously untreated patients with acute myeloid leukemia. Cancer Chemotherapy and Pharmacology. 28(6). 480–483. 19 indexed citations
18.
Mertens, Fredrik, Bengt Sallerfors, Sverre Heim, et al.. (1991). Trisomy 13 as a primary chromosome aberration in acute leukemia. Cancer Genetics and Cytogenetics. 56(1). 39–44. 12 indexed citations
19.
Grützmeier, Sven & Claes Malm. (1988). CRP concentration in a patient with acute leukaemia and bone marrow infarction. Medical Oncology and Tumor Pharmacotherapy. 5(3). 199–200. 2 indexed citations
20.
Hasselbalch, Hans Carl, Ida Maria Lisse, Birgitta Swolin, et al.. (1988). Recombinant interferon‐alpha‐2b treatment of hairy‐cell leukaemia: Experience with a low‐dose schedule. European Journal Of Haematology. 41(5). 438–444. 15 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by A. E. Watmore Breakdown of academic impact, for papers by Mordechai Shtalrid Breakdown of academic impact, for papers by Odile Maarek Breakdown of academic impact, for papers by Julian Topaly Breakdown of academic impact, for papers by Françoise Brizard Breakdown of academic impact, for papers by A. Nagler Breakdown of academic impact, for papers by Lihui Wang Breakdown of academic impact, for papers by B Heinze Breakdown of academic impact, for papers by CM Rubin Breakdown of academic impact, for papers by Paul Virgo
Rankless by CCL
2026